News Related to Nuclear Receptor Subfamily 4 Group A Member 2

Related coverage linked through entity extraction aliases.

Immunic Secures $400 Million Financing for Phase 3 MS Trials and Commercial Transition

Feb 14, 2026

Immunic announced an oversubscribed private placement of up to $400 million to complete phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a phase 3 program in primary progressive MS, and transition to a commercial organization.

Immunic Secures $400 Million Private Placement to Fund MS Trials and Commercial Transition

Feb 13, 2026

Immunic announced an oversubscribed private placement of up to $400 million to complete Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a Phase 3 trial in primary progressive MS, and transition into a commercial organization.